Trial Outcomes & Findings for Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment (NCT NCT02873936)

NCT ID: NCT02873936

Last Updated: 2021-05-13

Results Overview

ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in tender joint count based on 68 joints (TJC68), swollen joint count based on 66 joints (SJC66) and in at least 3 of the following 5 items: physician's global assessment of disease activity (PGA) and subject's global assessment of disease activity (SGA) assessed using visual analog scale (VAS) on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; health assessment questionnaire-disability index (HAQ-DI) score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; high-sensitivity C-reactive protein (hsCRP). Participants with missing outcomes were set as non-responders.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

449 participants

Primary outcome timeframe

Week 12

Results posted on

2021-05-13

Participant Flow

Participants were enrolled at study sites in Australia, Asia, Europe, North America, and South America. The first participant was screened on 27 July 2016. The last study visit occurred on 26 June 2018.

688 participants were screened. The enrolled participants continued to receive ongoing therapy with permitted protocol specified Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) (ie, methotrexate (MTX), hydroxychloroquine, sulfasalazine, or leflunomide). MTX was not permitted to be used in combination with leflunomide.

Participant milestones

Participant milestones
Measure
Filgotinib 200 mg
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Placebo
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Overall Study
STARTED
148
153
148
Overall Study
COMPLETED
135
130
116
Overall Study
NOT COMPLETED
13
23
32

Reasons for withdrawal

Reasons for withdrawal
Measure
Filgotinib 200 mg
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Placebo
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Overall Study
Withdrew Consent
4
11
20
Overall Study
Investigator's Discretion
3
5
4
Overall Study
Adverse Event
3
5
3
Overall Study
Protocol Violation
0
1
3
Overall Study
Lost to Follow-up
1
1
1
Overall Study
Non-compliance With Study Drug
1
0
1
Overall Study
Randomized but not Dosed
1
0
0

Baseline Characteristics

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Total
n=448 Participants
Total of all reporting groups
Age, Continuous
56.0 years
STANDARD_DEVIATION 12.5 • n=99 Participants
55.0 years
STANDARD_DEVIATION 12.0 • n=107 Participants
56.0 years
STANDARD_DEVIATION 12.1 • n=206 Participants
56.0 years
STANDARD_DEVIATION 12.2 • n=7 Participants
Sex: Female, Male
Female
120 Participants
n=99 Participants
119 Participants
n=107 Participants
121 Participants
n=206 Participants
360 Participants
n=7 Participants
Sex: Female, Male
Male
27 Participants
n=99 Participants
34 Participants
n=107 Participants
27 Participants
n=206 Participants
88 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · American Indian or Alaska Native
7 Participants
n=99 Participants
9 Participants
n=107 Participants
10 Participants
n=206 Participants
26 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Asian: Japanese
12 Participants
n=99 Participants
15 Participants
n=107 Participants
13 Participants
n=206 Participants
40 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Asian: Chinese/Taiwanese/Hong Kong Chinese
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Asian: Vietnamese
1 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
1 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Asian: Korean
2 Participants
n=99 Participants
2 Participants
n=107 Participants
1 Participants
n=206 Participants
5 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Asian: Other
0 Participants
n=99 Participants
3 Participants
n=107 Participants
1 Participants
n=206 Participants
4 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Black or African American
14 Participants
n=99 Participants
12 Participants
n=107 Participants
21 Participants
n=206 Participants
47 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Native Hawaiian or Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · White
110 Participants
n=99 Participants
109 Participants
n=107 Participants
97 Participants
n=206 Participants
316 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Other
1 Participants
n=99 Participants
3 Participants
n=107 Participants
2 Participants
n=206 Participants
6 Participants
n=7 Participants
Race/Ethnicity, Customized
Race · Not Permitted
0 Participants
n=99 Participants
0 Participants
n=107 Participants
3 Participants
n=206 Participants
3 Participants
n=7 Participants
Race/Ethnicity, Customized
Ethnicity · Hispanic or Latino
26 Participants
n=99 Participants
40 Participants
n=107 Participants
41 Participants
n=206 Participants
107 Participants
n=7 Participants
Race/Ethnicity, Customized
Ethnicity · Not Hispanic or Latino
120 Participants
n=99 Participants
112 Participants
n=107 Participants
107 Participants
n=206 Participants
339 Participants
n=7 Participants
Race/Ethnicity, Customized
Ethnicity · Not Permitted
1 Participants
n=99 Participants
1 Participants
n=107 Participants
0 Participants
n=206 Participants
2 Participants
n=7 Participants
Region of Enrollment
United States
87 Participants
n=99 Participants
84 Participants
n=107 Participants
84 Participants
n=206 Participants
255 Participants
n=7 Participants
Region of Enrollment
Spain
4 Participants
n=99 Participants
7 Participants
n=107 Participants
5 Participants
n=206 Participants
16 Participants
n=7 Participants
Region of Enrollment
Germany
8 Participants
n=99 Participants
4 Participants
n=107 Participants
3 Participants
n=206 Participants
15 Participants
n=7 Participants
Region of Enrollment
Belgium
4 Participants
n=99 Participants
3 Participants
n=107 Participants
6 Participants
n=206 Participants
13 Participants
n=7 Participants
Region of Enrollment
France
2 Participants
n=99 Participants
2 Participants
n=107 Participants
5 Participants
n=206 Participants
9 Participants
n=7 Participants
Region of Enrollment
United Kingdom
2 Participants
n=99 Participants
5 Participants
n=107 Participants
2 Participants
n=206 Participants
9 Participants
n=7 Participants
Region of Enrollment
South Korea
2 Participants
n=99 Participants
2 Participants
n=107 Participants
1 Participants
n=206 Participants
5 Participants
n=7 Participants
Region of Enrollment
Australia
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
4 Participants
n=7 Participants
Region of Enrollment
Israel
0 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
3 Participants
n=7 Participants
Region of Enrollment
Switzerland
1 Participants
n=99 Participants
1 Participants
n=107 Participants
0 Participants
n=206 Participants
2 Participants
n=7 Participants
Region of Enrollment
Poland
7 Participants
n=99 Participants
5 Participants
n=107 Participants
7 Participants
n=206 Participants
19 Participants
n=7 Participants
Region of Enrollment
Hungary
5 Participants
n=99 Participants
7 Participants
n=107 Participants
4 Participants
n=206 Participants
16 Participants
n=7 Participants
Region of Enrollment
Mexico
8 Participants
n=99 Participants
13 Participants
n=107 Participants
9 Participants
n=206 Participants
30 Participants
n=7 Participants
Region of Enrollment
Argentina
4 Participants
n=99 Participants
3 Participants
n=107 Participants
5 Participants
n=206 Participants
12 Participants
n=7 Participants
Region of Enrollment
Japan
12 Participants
n=99 Participants
15 Participants
n=107 Participants
13 Participants
n=206 Participants
40 Participants
n=7 Participants

PRIMARY outcome

Timeframe: Week 12

Population: The Full Analysis Set included all randomized participants who received at least 1 dose of study drug.

ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in tender joint count based on 68 joints (TJC68), swollen joint count based on 66 joints (SJC66) and in at least 3 of the following 5 items: physician's global assessment of disease activity (PGA) and subject's global assessment of disease activity (SGA) assessed using visual analog scale (VAS) on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; health assessment questionnaire-disability index (HAQ-DI) score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; high-sensitivity C-reactive protein (hsCRP). Participants with missing outcomes were set as non-responders.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12
31.1 percentage of participants
Interval 23.3 to 38.9
66.0 percentage of participants
Interval 58.0 to 74.0
57.5 percentage of participants
Interval 49.4 to 65.7

SECONDARY outcome

Timeframe: Baseline; Week 12

Population: Participants in the Full Analysis Set with available data were analyzed.

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0-3 \[0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices\]. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled)\] when 6 or more categories are non-missing, total possible score is 3. If more than 2 categories are missing, the HAQ-DI score is set to missing. Negative change from baseline indicates improvement (less disability).

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 12
Baseline
1.65 score on a scale
Standard Deviation 0.633
1.70 score on a scale
Standard Deviation 0.656
1.64 score on a scale
Standard Deviation 0.683
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 12
Change from Baseline at Week 12
-0.23 score on a scale
Standard Deviation 0.547
-0.55 score on a scale
Standard Deviation 0.590
-0.48 score on a scale
Standard Deviation 0.602

SECONDARY outcome

Timeframe: Week 12

Population: Participants in the Full Analysis Set were analyzed.

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and hsCRP (CRP=hsCRP) for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Percentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] ≤ 3.2 at Week 12
15.5 percentage of participants
Interval 9.4 to 21.7
40.8 percentage of participants
Interval 32.5 to 49.1
37.3 percentage of participants
Interval 29.3 to 45.2

SECONDARY outcome

Timeframe: Baseline; Week 12

Population: Participants in the Full Analysis Set with available data were analyzed.

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=146 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 12
Baseline
31.1 score on a scale
Standard Deviation 8.17
30.4 score on a scale
Standard Deviation 7.75
31.7 score on a scale
Standard Deviation 7.76
Change From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 12
Change from Baseline at Week 12
3.6 score on a scale
Standard Deviation 8.16
7.6 score on a scale
Standard Deviation 7.68
6.8 score on a scale
Standard Deviation 8.22

SECONDARY outcome

Timeframe: Week 24

Population: Participants in the Full Analysis Set were analyzed.

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), Patient's Global Assessment of Disease Activity (visual analog scale: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Week 24
12.2 percentage of participants
Interval 6.6 to 17.8
30.6 percentage of participants
Interval 22.8 to 38.4
26.1 percentage of participants
Interval 18.9 to 33.4

SECONDARY outcome

Timeframe: Baseline; Week 12

Population: Participants in the Full Analysis Set with available data were analyzed.

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

Outcome measures

Outcome measures
Measure
Placebo
n=147 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=146 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=152 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12
Baseline
25.4 score on a scale
Standard Deviation 10.89
24.2 score on a scale
Standard Deviation 11.47
23.7 score on a scale
Standard Deviation 12.30
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12
Change from Baseline at Week 12
4.5 score on a scale
Standard Deviation 10.37
9.6 score on a scale
Standard Deviation 11.24
8.3 score on a scale
Standard Deviation 10.80

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set were analyzed.

ACR50 response is achieved when the participant has: ≥50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Percentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 4, 12, and 24
Week 4
7.4 percentage of participants
Interval 2.9 to 12.0
22.4 percentage of participants
Interval 15.4 to 29.5
21.6 percentage of participants
Interval 14.7 to 28.4
Percentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 4, 12, and 24
Week 12
14.9 percentage of participants
Interval 8.8 to 20.9
42.9 percentage of participants
Interval 34.5 to 51.2
32.0 percentage of participants
Interval 24.3 to 39.7
Percentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 4, 12, and 24
Week 24
18.9 percentage of participants
Interval 12.3 to 25.6
45.6 percentage of participants
Interval 37.2 to 54.0
35.3 percentage of participants
Interval 27.4 to 43.2

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set were analyzed.

ACR70 response is achieved when the participant has: ≥70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 4, 12, and 24
Week 4
2.7 percentage of participants
Interval 0.0 to 5.7
6.1 percentage of participants
Interval 1.9 to 10.3
8.5 percentage of participants
Interval 3.8 to 13.2
Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 4, 12, and 24
Week 12
6.8 percentage of participants
Interval 2.4 to 11.1
21.8 percentage of participants
Interval 14.8 to 28.8
14.4 percentage of participants
Interval 8.5 to 20.3
Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 4, 12, and 24
Week 24
8.1 percentage of participants
Interval 3.4 to 12.8
32.0 percentage of participants
Interval 24.1 to 39.9
20.3 percentage of participants
Interval 13.6 to 27.0

SECONDARY outcome

Timeframe: Weeks 4, and 24

Population: Participants in the Full Analysis Set were analyzed.

ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Percentage of Participants Who Achieved ACR20 Response at Weeks 4, and 24
Week 4
25.7 percentage of participants
Interval 18.3 to 33.1
51.7 percentage of participants
Interval 43.3 to 60.1
44.4 percentage of participants
Interval 36.2 to 52.6
Percentage of Participants Who Achieved ACR20 Response at Weeks 4, and 24
Week 24
34.5 percentage of participants
Interval 26.5 to 42.5
69.4 percentage of participants
Interval 61.6 to 77.2
54.9 percentage of participants
Interval 46.7 to 63.1

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

TJC was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=146 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 4, 12, and 24
Baseline
27.0 tender joint count
Standard Deviation 15.5
28.0 tender joint count
Standard Deviation 16.1
26.0 tender joint count
Standard Deviation 15.4
Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 4, 12, and 24
Change from Baseline at Week 4
-8.0 tender joint count
Standard Deviation 13.8
-13.0 tender joint count
Standard Deviation 13.5
-11.0 tender joint count
Standard Deviation 11.0
Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 4, 12, and 24
Change from Baseline at Week 12
-12.0 tender joint count
Standard Deviation 13.4
-18.0 tender joint count
Standard Deviation 14.1
-16.0 tender joint count
Standard Deviation 11.8
Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 4, 12, and 24
Change from Baseline at Week 24
-17.0 tender joint count
Standard Deviation 13.3
-22.0 tender joint count
Standard Deviation 14.2
-19.0 tender joint count
Standard Deviation 13.0

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The total SJC66 was based on 66 joints (same 68 joints counted in TJC68 minus hips). It was derived as the sum of all "1s" (presence of a joint swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons) thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 is 0 to 66. A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=146 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 4, 12, and 24
Baseline
17.0 swollen joint count
Standard Deviation 9.7
18.0 swollen joint count
Standard Deviation 12.5
17.0 swollen joint count
Standard Deviation 12.4
Change From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 4, 12, and 24
Change from Baseline at Week 4
-7.0 swollen joint count
Standard Deviation 8.8
-10.0 swollen joint count
Standard Deviation 10.6
-7.0 swollen joint count
Standard Deviation 9.2
Change From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 4, 12, and 24
Change from Baseline at Week 12
-8.0 swollen joint count
Standard Deviation 8.9
-12.0 swollen joint count
Standard Deviation 10.5
-10.0 swollen joint count
Standard Deviation 8.6
Change From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 4, 12, and 24
Change from Baseline at Week 24
-12.0 swollen joint count
Standard Deviation 8.7
-14.0 swollen joint count
Standard Deviation 10.3
-13.0 swollen joint count
Standard Deviation 10.0

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

SGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 4, 12, and 24
Baseline
70.0 score on a scale
Standard Deviation 18.0
68.0 score on a scale
Standard Deviation 20.6
69.0 score on a scale
Standard Deviation 20.2
Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 4, 12, and 24
Change from Baseline at Week 4
-10.0 score on a scale
Standard Deviation 22.6
-21.0 score on a scale
Standard Deviation 23.2
-20.0 score on a scale
Standard Deviation 26.1
Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 4, 12, and 24
Change from Baseline at Week 12
-14.0 score on a scale
Standard Deviation 26.3
-31.0 score on a scale
Standard Deviation 25.9
-27.0 score on a scale
Standard Deviation 28.4
Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 4, 12, and 24
Change from Baseline at Week 24
-24.0 score on a scale
Standard Deviation 28.0
-38.0 score on a scale
Standard Deviation 26.8
-34.0 score on a scale
Standard Deviation 28.1

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

PGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 3 (maximum disease activity). A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 4, 12, and 24
Baseline
66.0 score on a scale
Standard Deviation 16.7
69.0 score on a scale
Standard Deviation 17.6
68.0 score on a scale
Standard Deviation 18.7
Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 4, 12, and 24
Change from Baseline at Week 4
-19.0 score on a scale
Standard Deviation 22.2
-32.0 score on a scale
Standard Deviation 25.2
-30.0 score on a scale
Standard Deviation 24.3
Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 4, 12, and 24
Change from Baseline at Week 12
-28.0 score on a scale
Standard Deviation 26.9
-45.0 score on a scale
Standard Deviation 25.2
-41.0 score on a scale
Standard Deviation 26.7
Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 4, 12, and 24
Change from Baseline at Week 24
-41.0 score on a scale
Standard Deviation 23.5
-53.0 score on a scale
Standard Deviation 22.7
-45.0 score on a scale
Standard Deviation 23.8

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 4, 12, and 24
Baseline
68.0 score on a scale
Standard Deviation 19.9
66.0 score on a scale
Standard Deviation 21.6
67.0 score on a scale
Standard Deviation 21.7
Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 4, 12, and 24
Change from Baseline at Week 4
-8.0 score on a scale
Standard Deviation 22.6
-22.0 score on a scale
Standard Deviation 24.2
-20.0 score on a scale
Standard Deviation 26.3
Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 4, 12, and 24
Change from Baseline at Week 12
-14.0 score on a scale
Standard Deviation 27.0
-30.0 score on a scale
Standard Deviation 27.9
-27.0 score on a scale
Standard Deviation 30.9
Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 4, 12, and 24
Change from Baseline at Week 24
-24.0 score on a scale
Standard Deviation 28.3
-37.0 score on a scale
Standard Deviation 28.1
-35.0 score on a scale
Standard Deviation 29.1

SECONDARY outcome

Timeframe: Baseline; Weeks 4, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 4, and 24
Change from Baseline at Week 24
-0.42 score on a scale
Standard Deviation 0.600
-0.75 score on a scale
Standard Deviation 0.620
-0.60 score on a scale
Standard Deviation 0.660
Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 4, and 24
Baseline
1.65 score on a scale
Standard Deviation 0.633
1.70 score on a scale
Standard Deviation 0.656
1.64 score on a scale
Standard Deviation 0.683
Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 4, and 24
Change from Baseline at Week 4
-0.18 score on a scale
Standard Deviation 0.444
-0.39 score on a scale
Standard Deviation 0.493
-0.32 score on a scale
Standard Deviation 0.539

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 4, 12, and 24
Baseline
16.42 mg/L
Standard Deviation 18.321
17.21 mg/L
Standard Deviation 18.275
21.49 mg/L
Standard Deviation 28.206
Change From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 4, 12, and 24
Change from Baseline at Week 4
1.04 mg/L
Standard Deviation 13.942
-9.55 mg/L
Standard Deviation 18.421
-12.15 mg/L
Standard Deviation 25.502
Change From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 4, 12, and 24
Change from Baseline at Week 12
0.57 mg/L
Standard Deviation 15.178
-11.86 mg/L
Standard Deviation 19.760
-12.02 mg/L
Standard Deviation 26.226
Change From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 4, 12, and 24
Change from Baseline at Week 24
-1.50 mg/L
Standard Deviation 15.889
-10.87 mg/L
Standard Deviation 19.083
-11.12 mg/L
Standard Deviation 27.766

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing, so total possible score is 3. Improvement is defined as reduction in HAQ-DI, (baseline value - postbaseline value) ≥ 0.22. If more than 2 categories are missing, the HAQ-DI score is set to missing. Participants with missing outcomes were set as non-responders.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 4, 12, and 24
Week 4
40.3 percentage of participants
Interval 31.9 to 48.6
60.4 percentage of participants
Interval 52.1 to 68.8
54.7 percentage of participants
Interval 46.4 to 63.1
Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 4, 12, and 24
Week 12
44.4 percentage of participants
Interval 36.0 to 52.9
66.7 percentage of participants
Interval 58.6 to 74.7
66.2 percentage of participants
Interval 58.3 to 74.2
Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 4, 12, and 24
Week 24
35.4 percentage of participants
Interval 27.3 to 43.6
68.8 percentage of participants
Interval 60.8 to 76.7
54.1 percentage of participants
Interval 45.7 to 62.4

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in DAS28 (CRP) at Weeks 4, 12, and 24
Baseline
5.9 score on a scale
Standard Deviation 0.86
5.9 score on a scale
Standard Deviation 1.03
5.9 score on a scale
Standard Deviation 0.98
Change From Baseline in DAS28 (CRP) at Weeks 4, 12, and 24
Change from Baseline at Week 4
-0.9 score on a scale
Standard Deviation 1.14
-1.7 score on a scale
Standard Deviation 1.16
-1.5 score on a scale
Standard Deviation 1.14
Change From Baseline in DAS28 (CRP) at Weeks 4, 12, and 24
Change from Baseline at Week 12
-1.3 score on a scale
Standard Deviation 1.33
-2.4 score on a scale
Standard Deviation 1.32
-2.3 score on a scale
Standard Deviation 1.38
Change From Baseline in DAS28 (CRP) at Weeks 4, 12, and 24
Change from Baseline at Week 24
-2.1 score on a scale
Standard Deviation 1.28
-2.9 score on a scale
Standard Deviation 1.29
-2.6 score on a scale
Standard Deviation 1.32

SECONDARY outcome

Timeframe: Weeks 4, and 24

Population: Participants in the Full Analysis Set were analyzed.

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 4, and 24
Week 4
9.5 percentage of participants
Interval 4.4 to 14.5
21.8 percentage of participants
Interval 14.8 to 28.8
22.2 percentage of participants
Interval 15.3 to 29.1
Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 4, and 24
Week 24
20.9 percentage of participants
Interval 14.1 to 27.8
48.3 percentage of participants
Interval 39.9 to 56.7
37.9 percentage of participants
Interval 29.9 to 45.9

SECONDARY outcome

Timeframe: Weeks 4, and 12

Population: Participants in the Full Analysis Set were analyzed.

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 4, and 12
Week 4
2.7 percentage of participants
Interval 0.0 to 5.7
10.2 percentage of participants
Interval 5.0 to 15.4
11.8 percentage of participants
Interval 6.3 to 17.2
Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 4, and 12
Week 12
8.1 percentage of participants
Interval 3.4 to 12.8
22.4 percentage of participants
Interval 15.4 to 29.5
25.5 percentage of participants
Interval 18.3 to 32.7

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject's pain assessment, HAQ-DI and hsCRP). It has a range between 0 and 100%. PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions,8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]. If this calculation results in a negative value, then the ACR-N is set to 0. The ACR-N value indicates an improvement of N%, with higher numbers indicating greater improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
American College of Rheumatology N Percent Improvement (ACR-N) at Weeks 4, 12, and 24
Week 4
13.7 percent improvement
Standard Deviation 19.42
26.9 percent improvement
Standard Deviation 24.58
25.8 percent improvement
Standard Deviation 27.09
American College of Rheumatology N Percent Improvement (ACR-N) at Weeks 4, 12, and 24
Week 12
19.7 percent improvement
Standard Deviation 25.44
43.4 percent improvement
Standard Deviation 29.26
37.1 percent improvement
Standard Deviation 30.29
American College of Rheumatology N Percent Improvement (ACR-N) at Weeks 4, 12, and 24
Week 24
31.9 percent improvement
Standard Deviation 29.52
53.5 percent improvement
Standard Deviation 27.52
45.5 percent improvement
Standard Deviation 32.16

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

Good Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>1.2. Moderate Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>0.6 and ≤1.2; DAS28(CRP) at visit \>3.2 and ≤5.1 and improvement from baseline \>0.6; DAS 28(CRP) at visit \>5.1 and improvement from baseline \>1.2. No Response: DAS28(CRP) at visit ≤5.1 and improvement from baseline ≤0.6; DAS 28(CRP) \>5.1 at visit and improvement from baseline ≤1.2.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24
Week 4 · Good Response
13 Participants
32 Participants
34 Participants
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24
Week 4 · Moderate Response
53 Participants
74 Participants
65 Participants
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24
Week 4 · No Response
63 Participants
38 Participants
46 Participants
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24
Week 12 · Good Response
23 Participants
58 Participants
56 Participants
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24
Week 12 · Moderate Response
51 Participants
65 Participants
58 Participants
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24
Week 12 · No Response
54 Participants
13 Participants
23 Participants
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24
Week 24 · Good Response
31 Participants
70 Participants
58 Participants
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24
Week 24 · Moderate Response
45 Participants
43 Participants
47 Participants
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 4, 12, and 24
Week 24 · No Response
12 Participants
8 Participants
6 Participants

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

CDAI is calculated using formula: CDAI = TJC based on 28 joints (TJC28) + SJC based on 28 joints (SJC28) + SGA + PGA. PGA and SGA are assessed using a VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. CDAI can range from 0 to 76, with higher score indicating more severe disease activity status. A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 4, 12, and 24
Baseline
41.4 score on a scale
Standard Deviation 12.00
41.7 score on a scale
Standard Deviation 14.23
40.4 score on a scale
Standard Deviation 13.23
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 4, 12, and 24
Change from Baseline at Week 4
-12.8 score on a scale
Standard Deviation 13.71
-19.1 score on a scale
Standard Deviation 13.06
-16.8 score on a scale
Standard Deviation 12.95
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 4, 12, and 24
Change from Baseline at Week 12
-17.3 score on a scale
Standard Deviation 15.22
-26.2 score on a scale
Standard Deviation 15.04
-23.8 score on a scale
Standard Deviation 14.33
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 4, 12, and 24
Change from Baseline at Week 24
-25.4 score on a scale
Standard Deviation 14.40
-30.9 score on a scale
Standard Deviation 13.77
-27.8 score on a scale
Standard Deviation 13.54

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

SDAI is a composite measure that sums the TJC28, SJC28, SGA, PGA, and the hsCRP (in mg/dL). PGA and SGA assessed using VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. Higher score indicates more severe disease activity status and total possible score is 0 to 86. A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 4, 12, and 24
Baseline
43.0 score on a scale
Standard Deviation 12.33
43.4 score on a scale
Standard Deviation 14.64
42.6 score on a scale
Standard Deviation 14.16
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 4, 12, and 24
Change from Baseline at Week 4
-12.9 score on a scale
Standard Deviation 14.01
-20.1 score on a scale
Standard Deviation 13.73
-18.1 score on a scale
Standard Deviation 13.19
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 4, 12, and 24
Change from Baseline at Week 12
-17.2 score on a scale
Standard Deviation 15.52
-27.6 score on a scale
Standard Deviation 15.54
-24.9 score on a scale
Standard Deviation 15.01
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 4, 12, and 24
Change from Baseline at Week 24
-24.9 score on a scale
Standard Deviation 14.84
-32.1 score on a scale
Standard Deviation 14.41
-28.8 score on a scale
Standard Deviation 14.19

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
SF-36 PCS Score at Weeks 4, 12, and 24
Week 4
33.7 score on a scale
Standard Deviation 8.67
35.4 score on a scale
Standard Deviation 8.72
36.4 score on a scale
Standard Deviation 9.29
SF-36 PCS Score at Weeks 4, 12, and 24
Week 12
35.1 score on a scale
Standard Deviation 9.90
38.3 score on a scale
Standard Deviation 10.14
38.6 score on a scale
Standard Deviation 9.39
SF-36 PCS Score at Weeks 4, 12, and 24
Week 24
37.7 score on a scale
Standard Deviation 9.09
40.4 score on a scale
Standard Deviation 9.64
40.3 score on a scale
Standard Deviation 10.31

SECONDARY outcome

Timeframe: Baseline; Weeks 4, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=146 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in SF-36 PCS Score at Weeks 4, and 24
Baseline
31.1 score on a scale
Standard Deviation 8.17
30.4 score on a scale
Standard Deviation 7.75
31.7 score on a scale
Standard Deviation 7.76
Change From Baseline in SF-36 PCS Score at Weeks 4, and 24
Change from Baseline at Week 4
2.5 score on a scale
Standard Deviation 5.91
5.1 score on a scale
Standard Deviation 6.34
4.5 score on a scale
Standard Deviation 6.53
Change From Baseline in SF-36 PCS Score at Weeks 4, and 24
Change from Baseline at Week 24
6.6 score on a scale
Standard Deviation 7.95
9.4 score on a scale
Standard Deviation 8.23
9.0 score on a scale
Standard Deviation 8.44

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
SF-36 Mental Component Summary (MCS) Score at Weeks 4, 12, and 24
Week 4
45.5 score on a scale
Standard Deviation 11.11
48.0 score on a scale
Standard Deviation 11.48
47.3 score on a scale
Standard Deviation 11.51
SF-36 Mental Component Summary (MCS) Score at Weeks 4, 12, and 24
Week 12
47.9 score on a scale
Standard Deviation 11.01
50.2 score on a scale
Standard Deviation 10.58
48.8 score on a scale
Standard Deviation 11.02
SF-36 Mental Component Summary (MCS) Score at Weeks 4, 12, and 24
Week 24
49.1 score on a scale
Standard Deviation 10.56
50.6 score on a scale
Standard Deviation 10.35
49.5 score on a scale
Standard Deviation 10.72

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=146 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in SF-36 MCS Score at Weeks 4, 12, and 24
Baseline
44.3 score on a scale
Standard Deviation 11.32
44.5 score on a scale
Standard Deviation 11.97
44.2 score on a scale
Standard Deviation 11.59
Change From Baseline in SF-36 MCS Score at Weeks 4, 12, and 24
Change from Baseline at Week 4
1.2 score on a scale
Standard Deviation 9.34
3.5 score on a scale
Standard Deviation 9.17
3.0 score on a scale
Standard Deviation 9.03
Change From Baseline in SF-36 MCS Score at Weeks 4, 12, and 24
Change from Baseline at Week 12
3.7 score on a scale
Standard Deviation 9.17
5.3 score on a scale
Standard Deviation 10.60
4.6 score on a scale
Standard Deviation 9.76
Change From Baseline in SF-36 MCS Score at Weeks 4, 12, and 24
Change from Baseline at Week 24
4.3 score on a scale
Standard Deviation 9.44
6.5 score on a scale
Standard Deviation 12.50
4.6 score on a scale
Standard Deviation 9.22

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
FACIT-Fatigue Score at Weeks 4, 12, and 24
Week 4
27.9 score on a scale
Standard Deviation 11.29
30.4 score on a scale
Standard Deviation 12.48
30.3 score on a scale
Standard Deviation 12.30
FACIT-Fatigue Score at Weeks 4, 12, and 24
Week 12
30.4 score on a scale
Standard Deviation 11.79
34.0 score on a scale
Standard Deviation 12.08
32.1 score on a scale
Standard Deviation 13.66
FACIT-Fatigue Score at Weeks 4, 12, and 24
Week 24
33.3 score on a scale
Standard Deviation 11.26
36.3 score on a scale
Standard Deviation 11.58
34.4 score on a scale
Standard Deviation 12.51

SECONDARY outcome

Timeframe: Baseline; Weeks 4, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

Outcome measures

Outcome measures
Measure
Placebo
n=147 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=146 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=152 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in FACIT-Fatigue Score at Weeks 4, and 24
Baseline
25.4 score on a scale
Standard Deviation 10.89
24.2 score on a scale
Standard Deviation 11.47
23.7 score on a scale
Standard Deviation 12.30
Change From Baseline in FACIT-Fatigue Score at Weeks 4, and 24
Change from Baseline at Week 4
2.2 score on a scale
Standard Deviation 8.92
6.2 score on a scale
Standard Deviation 10.20
6.4 score on a scale
Standard Deviation 9.87
Change From Baseline in FACIT-Fatigue Score at Weeks 4, and 24
Change from Baseline at Week 24
7.0 score on a scale
Standard Deviation 10.23
11.6 score on a scale
Standard Deviation 11.67
9.8 score on a scale
Standard Deviation 10.39

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and a rating of his or her current health state on a 0-100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 12 · Severe Problems
20 Participants
15 Participants
11 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 24 · Moderate Problems
10 Participants
13 Participants
16 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 24 · Severe Problems
4 Participants
4 Participants
4 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 24 · Extreme Problems
0 Participants
0 Participants
1 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 4 · No Problems
22 Participants
27 Participants
38 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 4 · Slight Problems
44 Participants
65 Participants
50 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 4 · Moderate Problems
49 Participants
26 Participants
38 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 4 · Severe Problems
25 Participants
19 Participants
12 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 4 · Extreme Problems
4 Participants
8 Participants
6 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 12 · No Problems
26 Participants
47 Participants
51 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 12 · Slight Problems
48 Participants
54 Participants
41 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 12 · Moderate Problems
38 Participants
25 Participants
37 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 12 · Extreme Problems
0 Participants
0 Participants
3 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 24 · No Problems
20 Participants
51 Participants
41 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 24 · Slight Problems
41 Participants
45 Participants
32 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 24 · Moderate Problems
24 Participants
18 Participants
28 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 24 · Severe Problems
4 Participants
8 Participants
7 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Usual Activities: Week 24 · Extreme Problems
1 Participants
1 Participants
2 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 4 · No Problems
3 Participants
8 Participants
11 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 4 · Slight Problems
37 Participants
69 Participants
57 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 4 · Moderate Problems
62 Participants
45 Participants
50 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 4 · Severe Problems
36 Participants
19 Participants
22 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 4 · Extreme Problems
6 Participants
4 Participants
4 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 12 · No Problems
10 Participants
21 Participants
16 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 12 · Slight Problems
36 Participants
68 Participants
56 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 12 · Moderate Problems
57 Participants
34 Participants
56 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 12 · Severe Problems
28 Participants
17 Participants
14 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 12 · Extreme Problems
1 Participants
1 Participants
1 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 24 · No Problems
10 Participants
18 Participants
20 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 24 · Slight Problems
32 Participants
61 Participants
42 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 24 · Moderate Problems
33 Participants
31 Participants
36 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 24 · Severe Problems
14 Participants
12 Participants
10 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Pain/Discomfort: Week 24 · Extreme Problems
1 Participants
1 Participants
2 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 4 · No Problems
60 Participants
78 Participants
77 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 4 · Slight Problems
43 Participants
33 Participants
41 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 4 · Moderate Problems
34 Participants
25 Participants
21 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 4 · Severe Problems
5 Participants
8 Participants
4 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 4 · Extreme Problems
2 Participants
1 Participants
1 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 12 · No Problems
71 Participants
79 Participants
84 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 12 · Slight Problems
34 Participants
33 Participants
30 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 12 · Moderate Problems
23 Participants
23 Participants
26 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 12 · Severe Problems
3 Participants
5 Participants
3 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 12 · Extreme Problems
1 Participants
1 Participants
0 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 24 · No Problems
50 Participants
70 Participants
62 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 24 · Slight Problems
19 Participants
33 Participants
30 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 24 · Moderate Problems
15 Participants
16 Participants
13 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 24 · Severe Problems
6 Participants
4 Participants
4 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Anxiety/Depression: Week 24 · Extreme Problems
0 Participants
0 Participants
1 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 4 · No Problems
32 Participants
34 Participants
45 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 4 · Slight Problems
49 Participants
58 Participants
49 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 4 · Moderate Problems
36 Participants
38 Participants
33 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 4 · Severe Problems
25 Participants
15 Participants
16 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 4 · Extreme Problems
2 Participants
0 Participants
1 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 12 · No Problems
38 Participants
47 Participants
57 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 12 · Slight Problems
46 Participants
55 Participants
48 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 12 · Moderate Problems
29 Participants
25 Participants
29 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 12 · Severe Problems
19 Participants
13 Participants
9 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 12 · Extreme Problems
0 Participants
1 Participants
0 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 24 · No Problems
32 Participants
51 Participants
38 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 24 · Slight Problems
29 Participants
38 Participants
45 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 24 · Moderate Problems
24 Participants
23 Participants
18 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 24 · Severe Problems
5 Participants
11 Participants
8 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Mobility: Week 24 · Extreme Problems
0 Participants
0 Participants
1 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 4 · No Problems
49 Participants
67 Participants
67 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 4 · Slight Problems
52 Participants
45 Participants
43 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 4 · Moderate Problems
28 Participants
24 Participants
27 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 4 · Severe Problems
11 Participants
6 Participants
6 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 4 · Extreme Problems
4 Participants
3 Participants
1 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 12 · No Problems
56 Participants
79 Participants
78 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 12 · Slight Problems
44 Participants
38 Participants
46 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 12 · Moderate Problems
21 Participants
16 Participants
15 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 12 · Severe Problems
11 Participants
6 Participants
4 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 12 · Extreme Problems
0 Participants
2 Participants
0 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 24 · No Problems
45 Participants
83 Participants
58 Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
Self-care: Week 24 · Slight Problems
31 Participants
23 Participants
31 Participants

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
EQ-5D Current Health VAS at Weeks 4, 12, and 24
Week 4
52.0 score on a scale
Standard Deviation 24.2
59.0 score on a scale
Standard Deviation 22.1
60.0 score on a scale
Standard Deviation 19.8
EQ-5D Current Health VAS at Weeks 4, 12, and 24
Week 12
58.0 score on a scale
Standard Deviation 23.0
66.0 score on a scale
Standard Deviation 23.2
65.0 score on a scale
Standard Deviation 22.2
EQ-5D Current Health VAS at Weeks 4, 12, and 24
Week 24
62.0 score on a scale
Standard Deviation 23.0
70.0 score on a scale
Standard Deviation 21.8
69.0 score on a scale
Standard Deviation 21.3

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health. Positive change indicates improvement (better health).

Outcome measures

Outcome measures
Measure
Placebo
n=147 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=146 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=152 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, and 24
Baseline
46.0 score on a scale
Standard Deviation 22.4
49.0 score on a scale
Standard Deviation 24.7
46.0 score on a scale
Standard Deviation 24.0
Change From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, and 24
Change from Baseline at Week 4
6.0 score on a scale
Standard Deviation 26.0
10.0 score on a scale
Standard Deviation 27.6
14.0 score on a scale
Standard Deviation 26.8
Change From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, and 24
Change from Baseline at Week 12
12.0 score on a scale
Standard Deviation 26.5
17.0 score on a scale
Standard Deviation 30.9
19.0 score on a scale
Standard Deviation 26.4
Change From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, and 24
Change from Baseline at Week 24
17.0 score on a scale
Standard Deviation 25.4
22.0 score on a scale
Standard Deviation 30.8
25.0 score on a scale
Standard Deviation 26.7

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA): Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
Week 4
14.3 percentage of work time missed
Standard Deviation 27.52
8.8 percentage of work time missed
Standard Deviation 21.01
18.2 percentage of work time missed
Standard Deviation 30.93
Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA): Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
Week 12
12.1 percentage of work time missed
Standard Deviation 24.39
5.6 percentage of work time missed
Standard Deviation 13.79
14.6 percentage of work time missed
Standard Deviation 27.13
Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA): Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
Week 24
8.5 percentage of work time missed
Standard Deviation 18.08
7.6 percentage of work time missed
Standard Deviation 16.37
13.8 percentage of work time missed
Standard Deviation 26.23

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
Week 4
48.6 percentage of impairment while working
Standard Deviation 29.81
27.4 percentage of impairment while working
Standard Deviation 22.50
37.8 percentage of impairment while working
Standard Deviation 25.43
WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
Week 12
44.2 percentage of impairment while working
Standard Deviation 29.21
23.9 percentage of impairment while working
Standard Deviation 20.99
34.8 percentage of impairment while working
Standard Deviation 27.22
WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
Week 24
36.7 percentage of impairment while working
Standard Deviation 26.95
28.0 percentage of impairment while working
Standard Deviation 27.57
25.6 percentage of impairment while working
Standard Deviation 22.10

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
Week 4
51.3 percentage of overall work productivity
Standard Deviation 30.85
30.8 percentage of overall work productivity
Standard Deviation 24.36
43.1 percentage of overall work productivity
Standard Deviation 27.82
WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
Week 12
46.9 percentage of overall work productivity
Standard Deviation 30.63
26.9 percentage of overall work productivity
Standard Deviation 24.20
39.5 percentage of overall work productivity
Standard Deviation 29.37
WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
Week 24
39.8 percentage of overall work productivity
Standard Deviation 29.49
31.7 percentage of overall work productivity
Standard Deviation 29.94
31.4 percentage of overall work productivity
Standard Deviation 25.65

SECONDARY outcome

Timeframe: Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity.

Outcome measures

Outcome measures
Measure
Placebo
n=148 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=147 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
Week 4
60.3 percentage of activity impairment
Standard Deviation 25.49
49.6 percentage of activity impairment
Standard Deviation 26.56
49.9 percentage of activity impairment
Standard Deviation 27.43
WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
Week 12
53.0 percentage of activity impairment
Standard Deviation 27.26
40.3 percentage of activity impairment
Standard Deviation 26.75
45.5 percentage of activity impairment
Standard Deviation 28.23
WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
Week 24
45.7 percentage of activity impairment
Standard Deviation 25.57
33.3 percentage of activity impairment
Standard Deviation 24.61
37.5 percentage of activity impairment
Standard Deviation 27.00

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=48 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=35 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=54 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
Baseline
10.8 percentage of work time missed
Standard Deviation 25.65
11.3 percentage of work time missed
Standard Deviation 16.31
19.2 percentage of work time missed
Standard Deviation 28.57
Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
Change from Baseline at Week 4
4.0 percentage of work time missed
Standard Deviation 20.75
-4.3 percentage of work time missed
Standard Deviation 20.98
-3.4 percentage of work time missed
Standard Deviation 24.57
Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
Change from Baseline at Week 12
3.8 percentage of work time missed
Standard Deviation 18.40
-3.6 percentage of work time missed
Standard Deviation 17.60
-7.0 percentage of work time missed
Standard Deviation 30.93
Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
Change from Baseline at Week 24
3.7 percentage of work time missed
Standard Deviation 25.13
-4.6 percentage of work time missed
Standard Deviation 22.50
-3.1 percentage of work time missed
Standard Deviation 34.28

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=46 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=35 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=51 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
Baseline
55.7 percentage of impairment while working
Standard Deviation 26.64
46.9 percentage of impairment while working
Standard Deviation 24.71
51.0 percentage of impairment while working
Standard Deviation 27.95
Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
Change from Baseline at Week 4
-5.3 percentage of impairment while working
Standard Deviation 25.52
-19.1 percentage of impairment while working
Standard Deviation 25.63
-13.1 percentage of impairment while working
Standard Deviation 25.75
Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
Change from Baseline at Week 12
-10.8 percentage of impairment while working
Standard Deviation 20.32
-20.0 percentage of impairment while working
Standard Deviation 25.56
-18.8 percentage of impairment while working
Standard Deviation 28.64
Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
Change from Baseline at Week 24
-20.0 percentage of impairment while working
Standard Deviation 31.36
-18.6 percentage of impairment while working
Standard Deviation 22.48
-28.7 percentage of impairment while working
Standard Deviation 25.26

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=46 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=35 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=51 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
Baseline
56.7 percentage of overall work productivity
Standard Deviation 27.60
52.0 percentage of overall work productivity
Standard Deviation 24.02
55.8 percentage of overall work productivity
Standard Deviation 30.53
Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
Change from Baseline at Week 4
-3.4 percentage of overall work productivity
Standard Deviation 25.48
-20.9 percentage of overall work productivity
Standard Deviation 28.94
-12.3 percentage of overall work productivity
Standard Deviation 28.05
Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
Change from Baseline at Week 12
-8.3 percentage of overall work productivity
Standard Deviation 20.16
-22.8 percentage of overall work productivity
Standard Deviation 29.20
-19.5 percentage of overall work productivity
Standard Deviation 31.49
Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
Change from Baseline at Week 24
-16.7 percentage of overall work productivity
Standard Deviation 33.28
-20.5 percentage of overall work productivity
Standard Deviation 26.20
-26.4 percentage of overall work productivity
Standard Deviation 29.87

SECONDARY outcome

Timeframe: Baseline; Weeks 4, 12, and 24

Population: Participants in the Full Analysis Set with available data were analyzed.

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Outcome measures

Outcome measures
Measure
Placebo
n=147 Participants
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Filgotinib 200 mg
n=146 Participants
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=152 Participants
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
Baseline
65.4 percentage of activity impairment
Standard Deviation 23.33
65.6 percentage of activity impairment
Standard Deviation 22.16
64.6 percentage of activity impairment
Standard Deviation 23.07
Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
Change from Baseline at Week 4
-4.7 percentage of activity impairment
Standard Deviation 25.06
-16.0 percentage of activity impairment
Standard Deviation 24.64
-14.3 percentage of activity impairment
Standard Deviation 22.89
Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
Change from Baseline at Week 12
-11.3 percentage of activity impairment
Standard Deviation 25.75
-25.0 percentage of activity impairment
Standard Deviation 26.81
-19.2 percentage of activity impairment
Standard Deviation 28.32
Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
Change from Baseline at Week 24
-18.4 percentage of activity impairment
Standard Deviation 31.23
-32.5 percentage of activity impairment
Standard Deviation 27.37
-27.1 percentage of activity impairment
Standard Deviation 27.97

Adverse Events

Filgotinib 200 mg

Serious events: 6 serious events
Other events: 39 other events
Deaths: 0 deaths

Filgotinib 100 mg

Serious events: 8 serious events
Other events: 35 other events
Deaths: 0 deaths

Placebo

Serious events: 5 serious events
Other events: 31 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Filgotinib 200 mg
n=147 participants at risk
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 participants at risk
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Placebo
n=148 participants at risk
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Blood and lymphatic system disorders
Anaemia
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.65%
1/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Cardiac disorders
Myocardial ischaemia
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.65%
1/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Ear and labyrinth disorders
Vertigo
0.68%
1/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Gastrointestinal disorders
Diarrhoea
0.68%
1/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Gastrointestinal disorders
Nausea
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.68%
1/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Gastrointestinal disorders
Vomiting
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.68%
1/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
General disorders
Chest pain
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.68%
1/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
General disorders
Systemic inflammatory response syndrome
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.68%
1/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Infections and infestations
Abscess oral
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.65%
1/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Infections and infestations
Bronchitis
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.65%
1/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Infections and infestations
Cellulitis
0.68%
1/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Infections and infestations
Gallbladder empyema
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.65%
1/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Infections and infestations
Gastroenteritis
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
1.4%
2/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Infections and infestations
Vulval abscess
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.65%
1/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Injury, poisoning and procedural complications
Concussion
0.68%
1/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Injury, poisoning and procedural complications
Laceration
0.68%
1/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Injury, poisoning and procedural complications
Lumbar vertebral fracture
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.68%
1/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Injury, poisoning and procedural complications
Rib fracture
0.68%
1/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Injury, poisoning and procedural complications
Subarachnoid haemorrhage
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.68%
1/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders
Dehydration
0.68%
1/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.68%
1/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders
Hyponatraemia
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.68%
1/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Metabolism and nutrition disorders
Lactic acidosis
0.68%
1/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Musculoskeletal and connective tissue disorders
Bursitis
0.68%
1/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.65%
1/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Musculoskeletal and connective tissue disorders
Osteitis
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.65%
1/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.68%
1/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Psychiatric disorders
Depression
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.65%
1/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Reproductive system and breast disorders
Uterine haemorrhage
0.68%
1/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders
Dyspnoea
0.00%
0/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.68%
1/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
0.68%
1/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
0.00%
0/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Other adverse events

Other adverse events
Measure
Filgotinib 200 mg
n=147 participants at risk
Participants were administered filgotinib 200 mg tablet orally, once daily + placebo to match (PTM) filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24.1 weeks.
Filgotinib 100 mg
n=153 participants at risk
Participants were administered filgotinib 100 mg tablet orally, once daily + PTM filgotinib 200 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Placebo
n=148 participants at risk
Participants were administered PTM filgotinib 200 mg tablet orally, once daily + PTM filgotinib 100 mg tablet orally, once daily + stable dose of permitted csDMARDs for median exposure of 24 weeks.
Gastrointestinal disorders
Nausea
4.8%
7/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
5.2%
8/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
3.4%
5/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Infections and infestations
Bronchitis
5.4%
8/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
2.0%
3/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
5.4%
8/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Infections and infestations
Nasopharyngitis
10.2%
15/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
5.9%
9/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
4.7%
7/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Infections and infestations
Upper respiratory tract infection
5.4%
8/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
5.9%
9/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
4.1%
6/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Musculoskeletal and connective tissue disorders
Rheumatoid arthritis
1.4%
2/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
1.3%
2/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
5.4%
8/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
Nervous system disorders
Headache
5.4%
8/147 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
5.9%
9/153 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
1.4%
2/148 • First dose date up to last dose date (Maximum: 29.3 weeks) plus 30 days
The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Additional Information

Gilead Clinical Study Information Center

Gilead Sciences

Phone: 1-833-445-3230 (GILEAD-0)

Results disclosure agreements

  • Principal investigator is a sponsor employee After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met: * The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or * The study has been completed at all study sites for at least 2 years
  • Publication restrictions are in place

Restriction type: OTHER